Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899646 · ClinicalTrials.gov registry record · NA
EXOMIND (BTL-699-2) for Improvement of Mental Well-being
A NA study, sponsored by BTL Industries.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT06899646 is a NA study that has completed, run by BTL Industries. The registered enrollment target is 38 participants.
The verdict
NCT06899646, a NA study, has completed, sponsored by BTL Industries.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate if the treatment with EXOMIND (BTL-699-2) device is able to improve mental well-being in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve mental well-being? Participants will be asked to: * Undergo four treatments * Complete the Warwick Edinburgh Mental Well-being Scale * Complete the Therapy Comfort Questionnaire * Complete the Subject Satisfaction \& Mental Wellness Questionnaire
Interventions
- DEVICE Treatment with BTL-699-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-07-08 |
| Est. Completion | 2025-02-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06899646
The ClinicalTrials.gov registry entry for NCT06899646 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BTL Industries, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment with BTL-699-2 is the first listed.
NCT06899646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06899646 about?
NCT06899646 is a clinical study titled "EXOMIND (BTL-699-2) for Improvement of Mental Well-being". The goal of this clinical trial is to evaluate if the treatment with EXOMIND (BTL-699-2) device is able to improve mental well-being in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve mental well-being? Participan...
What is the current status of trial NCT06899646?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2024-07-08. Estimated completion is 2025-02-03.
What interventions are being tested in trial NCT06899646?
The interventions under investigation include: Treatment with BTL-699-2 (DEVICE).
Who is sponsoring clinical trial NCT06899646?
This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.